GlycoNex to Attend 2024 BIO Convention

May 30, 2024 — GlycoNex, Inc. (GNX), a clinical-stage biotechnology company devoted to developing glycan-focused cancer immunotherapies, will be participating in the upcoming BIO International Convention in San Diego, California, from June 3 to June 6, 2024.

The company is enthusiastic about presenting its advanced cancer treatments that target sugar molecules—an innovative approach in immunotherapy. GlycoNex's leading project is GNX102, an antibody-drug conjugate (ADC) showing significant potential in treating challenging cancers such as gastric and bladder cancer. According to Dr. Mei-Chun Yang, CEO of GlycoNex, partnerships have been fundamental to their strategy, and they are eager to explore new opportunities at the convention to further their mission.

Throughout the event, Dr. Yang will engage in one-on-one discussions with pharmaceutical industry leaders to seek collaboration and strategic partnerships, particularly for GNX102 and the broader anti-cancer pipeline GlycoNex is developing.

About GlycoNex Inc.

GlycoNex Inc. is at the forefront of biotechnology, concentrating on the development of glycan-focused cancer immunotherapies that aim to inhibit tumor growth with minimal side effects. The company’s innovative pipeline is spearheaded by GNX102, a humanized monoclonal antibody (mAb) designed to target atypical sugar molecules found in cancer cells. GNX102 has completed Phase 1 clinical trials, demonstrating both excellent safety and promising efficacy.

In addition to GNX102, GlycoNex is advancing a suite of antibody-drug conjugates (ADCs) tailored to precisely attack cancer cells while sparing healthy tissue. The company is headquartered in New Taipei City, Taiwan.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!